1. Frei E. Curative cancer chemotherapy. Cancer Res 1985; 45:6523–37.
2. Lluch A, et al. Stage IIIB breast cancer treatment. In: EduardoDiaz-Rubio, editor. Cancer de mama. Madrid: Glaxo, 1993;p. 103–6.
3. Giulani FC, Coirin AK, Rice MR, Kaplan NO. Effect of 4′-doxorubicin analogues or heterotransplantation of human tumors in congenitally athimic mice. Cancer Treat Rep 1981;65:1063–75.
4. Fountzilas G, Inone S, Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mytoxantrone in acute myelogenic leukemia cells in culture. Leukemia 1990;4:321–4.
5. Jain KK, Casper ES, Geler NL, et al. A prospective randomised comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985;3:818–26.